Skip to main content
Medical information Clinical review pending

Genetic Testing

Mi Molecular Intelligence Tumor Seek Test

The Mi Molecular Intelligence Tumor Seek Test uses advanced molecular techniques to analyze tumor samples, providing oncologists with crucial insights for personalized cancer treatment planning.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Formalin-fixed paraffin-embedded (FFPE) tumor tissue block.
Results
Results are typically available within 30 working days after sample receipt.
Preparation
The FFPE tissue block must contain more than 20% tumor tissue. The surface area should be a minimum of 25 mm² (5mm x 5mm). A completed Tumor Profiling Requisition Form (Form 47) and the corresponding Histopathology report are required.
Test priceKSh 936,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Mi Molecular Intelligence Tumor Seek Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Patients with diagnosed cancers requiring detailed genetic information for treatment planning.
  • ✓Individuals with symptoms suggesting advanced disease or treatment resistance.
  • ✓Patients with a family history of cancer or suspected genetic predisposition.
  • ✓Oncologists seeking to identify specific tumor characteristics for personalized medicine.
  • ✓Patients exploring eligibility for clinical trials based on tumor genetics.
  • ✓Understanding tumor behavior through TMB and MSI analysis.
  • ✓Assessing gene expression profiles via Whole Transcriptome analysis.
02

In plain language

What this test helps you understand

Provides comprehensive molecular profiling of tumors to guide personalized cancer treatment strategies, identify potential targeted therapies, and understand prognosis.
The Mi Molecular Intelligence Tumor Seek Test is a state-of-the-art diagnostic tool that utilizes next-generation sequencing (NGS) to analyze tumor samples at a molecular level. This test is crucial for oncologists seeking to understand the genetic makeup of tumors, which can inform treatment decisions and improve patient outcomes. By providing detailed insights into tumor characteristics, this test plays a vital role in personalized medicine, allowing for tailored treatment strategies.

This comprehensive test measures several key components:

* Whole Exome (NGS DNA): Analyzes the coding regions of the genome to identify mutations. * MSI (Microsatellite Instability): Assesses the stability of microsatellite regions, which can indicate certain types of cancer. * TMB (Tumor Mutational Burden): Evaluates the total number of mutations within the tumor, providing insights into the tumor's behavior. * Whole Transcriptome (NGS RNA): Examines gene expression profiles to understand tumor biology.

Results from the Mi Molecular Intelligence Tumor Seek Test will be reported in a detailed format. Patients and their oncologists will receive comprehensive insights into the tumor's genetic landscape, which will aid in understanding the implications for treatment options. It is essential to discuss these results in detail with your healthcare provider for personalized guidance.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationThe FFPE tissue block must contain more than 20% tumor tissue. The surface area should be a minimum of 25 mm² (5mm x 5mm). A completed Tumor Profiling Requisition Form (Form 47) and the corresponding Histopathology report are required.
SampleFormalin-fixed paraffin-embedded (FFPE) tumor tissue block.
MethodologyNext-Generation Sequencing (NGS) for Whole Exome (DNA), Whole Transcriptome (RNA), Microsatellite Instability (MSI) analysis, and Tumor Mutational Burden (TMB) assessment.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
The test requires adequate tumor tissue in the FFPE block. Results are based on the genetic material present in the sample provided. Interpretation requires clinical correlation by a qualified healthcare professional.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

This is an advanced genetic test using Next-Generation Sequencing (NGS) to analyze the DNA and RNA of a tumor sample, providing detailed information about its genetic makeup.
This test is recommended for patients diagnosed with cancer, especially when detailed genetic information is needed to guide treatment decisions, understand prognosis, or explore targeted therapies.
A formalin-fixed paraffin-embedded (FFPE) block of tumor tissue is required. Specific requirements regarding tumor percentage and block size apply.
Results are typically available within 30 working days from the time the sample is received by the laboratory.
Results are provided in a detailed report. It is essential to discuss these findings with your oncologist to understand their implications for your specific situation.
You can book the test by contacting us via phone or WhatsApp at +254711564616. Our team will assist you with the process.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp